key: cord-0908553-4veygv3n authors: Hingrat, Quentin LE.; Visseaux, Benoit; Laouenan, Cédric; Tubiana, Sarah; Bouadma, Lila; Yazdanpanah, Yazdan; Duval, Xavier; Burdet, Charles; Ichou, Houria; Damond, Florence; Bertine, Mélanie; Benmalek, Nabil title: Detection of SARS-CoV-2 N-antigen in blood during acute COVID-19 provides a sensitive new marker and new testing alternatives date: 2020-12-09 journal: Clin Microbiol Infect DOI: 10.1016/j.cmi.2020.11.025 sha: 46a3c5a6fc1b27605acd937d9b2ca95f973c8d42 doc_id: 908553 cord_uid: 4veygv3n OBJECTIVES: Molecular assays on nasopharyngeal swabs remain the cornerstone of COVID-19 diagnostic. The high technicalities of nasopharyngeal sampling and molecular assays, as well as scarce resources of reagents, limit our testing capabilities. Several strategies failed, to date, to fully alleviate this testing process (e.g. saliva sampling or antigen testing on nasopharyngeal samples). We assessed the clinical performances of SARS-CoV-2 nucleocapsid antigen (N-antigen) ELISA detection in serum or plasma using the COVID-19 Quantigene® (AAZ, France) assay. METHODS: Performances were determined on 63 sera from 63 non-COVID patients and 227 serum samples (165 patients) from the French COVID and CoV-CONTACT cohorts with RT-PCR confirmed SARS-CoV-2 infection, including 142 serum (114 patients) obtained within 14 days after symptoms’ onset. RESULTS: Specificity was 98.4% (95% confidence interval [CI], 95.3 to 100). Sensitivity was 79.3% overall (180/227, 95% CI, 74.0 to 84.6) and 93.0% (132/142, 95% CI, 88.7 to 97.2) within 14 days after symptoms onset. 91 included patients had a sera and nasopharyngeal swabs collected in the same 24 hours. Among those with high nasopharyngeal viral loads, i.e. Ct value below 30 and 33, only 1/50 and 4/67 tested negative for N-antigenemia, respectively. Among those with a negative nasopharyngeal RT-PCR, 8/12 presented positive N-antigenemia; the lower respiratory tract was explored for 6 of these 8 patients, showing positive RT-PCR in 5 cases. CONCLUSION: This is the first evaluation of a commercially available serum N-antigen detection assay. It presents a robust specificity and sensitivity within the first 14 days after symptoms onset. This approach provides a valuable new option for COVID-19 diagnosis, only requiring a blood draw and easily scalable in all clinical laboratories. Molecular assays on nasopharyngeal swabs remain the cornerstone of COVID-19 diagnostic. Despite massive efforts, the high technicalities of nasopharyngeal sampling and molecular assays, as well as scarce resources of reagents, limit our testing capabilities. Several strategies failed, to date, to fully alleviate this testing process, e.g. saliva sampling [1, 2] or antigen testing on nasopharyngeal samples [3, 4] . Nucleocapsid-antigen (N-antigen) has been detected in the serum of SARS-CoV-infected patients and, recently, it has been demonstrated in SARS-CoV-2 infected patients by a single study with a global sensitivity of 41/64 patients [5, 6] . In this work, we assessed the performances of N-antigen sera detection in a large patients' population using the first commercially available assay, the COVID-19 Quantigene® (AAZ France) providing a low limit of detection at 2.98 pg/mL. Negative samples are composed of 50 pre-pandemic samples (collected between December 2, 2019 and January 13, 2020) and 13 pandemic samples from SARS-CoV-2 noninfected patients that tested positive for other microbial antigens (i.e. NS1 antigen, HBs antigen, HIV-1 p24 antigen, HKU1 coronavirus or malaria antigens). Positive samples were collected between January 25, 2020 and September 2, 2020 from study participants included in the French COVID (clinicaltrials.gov NCT04262921) and CoV-CONTACT cohorts (clinicaltrials.gov NCT04259892). We selected the first serum samples available after COVID-19 diagnosis (cf. Supplementary Figure 2 ). The following serum samples of those patients, when collected at physician discretion, were also included. They have provided written informed consent for the use of their samples for research. Ethics approval was given by the French Ethics Committee CPP-Ile-de-France 6 (ID RCB: 2020-A00256-33 and ID RCB: 2020-A00280-39) and the French National Data Protection Commission (approval #920102). After 15 minutes at 37°C, the colorimetric reaction was stopped by adding 50 µL of H 2 SO 4 . Absorbance values were measured at 450nm, with a reference set at 630nm. In each plate, standards made of recombinant N antigens were tested, to quantify the N antigenemia levels for each patient's sample. As the purpose of this study was to assess the sensitivity of this new assay, samples with titers above 180 pg/mL were not diluted for precise quantification. This is the first evaluation of a commercially available SARS-CoV-2 N-antigen serum or plasma detection. This assay presented a low detection limit at 2.98 pg/mL and a sensitivity above 90% during the acute phase of the disease (i.e. <14 days after symptoms onset in PCR confirmed COVID-(6/10) and/or low nasopharyngeal viral load in the same 24 hours (7/7, Ct value >30). This sensitivity could allow its use for COVID-19 diagnostic and is in line with RT-PCR on NP samples whose reported sensitivity rates ranged between 71 and 98%, based on negative RT-PCR tests which were positive on repeat testing [8] . Detection of viral antigens in the blood of COVID-19 patients has been recently described by Ogata and collaborators, who detected N and S1 antigens in the blood of 41 out of 64 COVID-19 patients [5] . If antigens blood circulation is not uncommon in infectious diseases, antigenemia tests usually target blood-borne pathogens, notably Dengue, CMV, HBV or HIV. In respiratory diseases, antigen circulation into non-respiratory body fluids is usually not considered, even if likely, because of the focal nature of the infection or possible pre-existence of antibodies. Antigen detection in nonrespiratory fluids is still used for two respiratory bacteria: Streptococcus pneumonia and Legionella pneumophila. Interestingly, it has also been reported in SARS-CoV-1 infection [6] . Whether the circulation of free viral antigens has an impact on disease physiopathology should be assessed in future studies. N-antigenemia was also detectable in outpatients but the decrease seems to occur earlier in our study. Detection of viral antigens in this population was not evaluated in the study by Ogata and collaborators. Detection of N-antigenemia was higher for patients with either high NP viral loads, i.e. This innovative marker may also be of help for prognostic evaluation of patients. An association between high N-antigen levels and higher ICU admission rates has been reported by Ogata et al. [5] . In our study, we observed higher N-antigen levels in serum of viremic patients, in line with the possible association of viremia, or RNAemia, with disease severity and/or immunosuppression [9] [10] [11] . Our study presents several limitations. We included a very few number of outpatients and this population needs to be explored in larger cohorts, ideally with longitudinal samples of paucisymptomatic and asymptomatic patients. The case-control design is another limitation and the test performances could be slightly deteriorated in real life condition. In conclusion, sensitive N-antigen detection in serum or plasma provides a valuable new marker for COVID-19 diagnosis, only requiring a blood draw, scalable in all clinical laboratories. It allows potential new developments to design rapid antigen blood test or combined ELISA assays, detecting both antigens and antibodies. It also raises new questions about the physiological mechanisms at play explaining blood circulation of this antigen and its potential correlation to disease severity. This study has been funded in part by the REACTing (REsearch & ACTion emergING infectious diseases) consortium, by a grant from the French Ministry of Health (PHRC n°20-0424) and by the ANRS (Agence Nationale de la Recherche sur le SIDA et les hépatites virales). The study was supported by AAZ (Boulogne-Billancourt, France) in the form of free consumables and they had no role in conceptualization, design, data collection and analyses, decision to publish and manuscript preparation. The French COVID cohort was sponsored by Inserm. We wish to thank the ANRS (Agence Nationale de la Recherche sur le SIDA et les hépatites virales). Comparing nasopharyngeal swab and early morning saliva for the identification of SARS-CoV-2 Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2 Clinical and laboratory evaluation of SARS-CoV-2 lateral flow assays for use in a national COVID-19 seroprevalence survey point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection Ultra-sensitive Serial Profiling of SARS-CoV-2 Antigens and Antibodies in Plasma to Understand Disease Progression in COVID-19 Patients with Severe Disease A Patient with Asymptomatic Severe Acute Respiratory Syndrome (SARS) and Antigenemia from the 2003-2004 Community Outbreak of SARS in Guangzhou, China Protocol: Real-time RT-PCR assays for the detection of SARS-CoV-2 Institut Pasteur False-negative results of initial RT-PCR assays for COVID-19: a systematic review Highly sensitive quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients A. D.B.